18F-FDG is the PET tracer most commonly used in nuclear medicine today. 18F-FDG is a structurally poorly altered, radioactively labeled sugar. After injection into the body, the tracer is distributed in the tissues and is absorbed by the cells that have a high turnover of sugar (brain, heart, malignant tumors and metastases).
On the axial fused images, focal FDG additional enrichments can be assigned to the anatomical structures. Thanks to the additional CT examination, the size and local extent of the primary tumor can be determined (yellow arrow). In addition, metastases can be detected in lymph nodes or other organs, as in this case a rib metastasis (red arrow).
The following indications for an 18F-FDG-PET examination are established and reimbursed by the health insurance company:
Senior Attending Physician, Vice Director of the Institute, Department of Nuclear Medicine
Attending Physician, Department of Nuclear Medicine
Attending Physician, Department of Nuclear Medicine
Attending Physician with extended responsibilites, Department of Nuclear Medicine
Attending Physician, Department of Nuclear Medicine
Attending Physician with extended responsibilites, Department of Nuclear Medicine
As a patient, you cannot register directly for a consultation. Please have your family doctor, specialist refer you. If you have any questions, please use our contact form.
Simply assign your patient via registration form.
Medical information hotline: 08.00-18.00 o’clock: +41 44 255 15 02